ReviewCurrent opinion in investigational drugs (London, England : 2000)2009
Measles control--can measles virus inhibitors make a difference?
Review in Current opinion in investigational drugs (London, England : 2000), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Viral threats to pregnancy: Global health risks in the era of pandemics.Advances in virus research · 2026Review
- Glycosylation as a strategic mechanism for measles virus and mumps virus immune evasion.Frontiers in immunology · 2025Review
- Immunological landscape of human lymphoid explants during measles virus infection.JCI insight · 2024Article
- Helical peptides with disordered regions for measles viruses provide new generalized insights into fusion inhibitors.iScience · 2024Article
- Medicinal plants of the upper Aswa River catchment of northern Uganda - a cultural crossroads.Journal of ethnobiology and ethnomedicine · 2023Article
- Opportunistic etiological agents causing lung infections: emerging need to transform lung-targeted delivery.Heliyon · 2022Review
- Small-molecule polymerase inhibitor protects non-human primates from measles and reduces shedding.Nature communications · 2021Article
- Therapeutic targeting of measles virus polymerase with ERDRP-0519 suppresses all RNA synthesis activity.PLoS pathogens · 2021Article
- Review
- Measles Resurgence and Drug Development.Current opinion in virology · 2020Review
- Measles Virus Bearing Measles Inclusion Body Encephalitis-Derived Fusion Protein Is Pathogenic after Infection via the Respiratory Route.Journal of virology · 2019Article
- Public health responses during measles outbreaks in elimination settings: Strategies and challenges.Human vaccines & immunotherapeutics · 2018Review
- Organization, Function, and Therapeutic Targeting of the Morbillivirus RNA-Dependent RNA Polymerase Complex.Viruses · 2016Review
- A pioneering countermeasure against measles virus.Annals of translational medicine · 2015Article
- The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics.Frontiers in microbiology · 2015Review
- Synergizing vaccinations with therapeutics for measles eradication.Expert opinion on drug discovery · 2014Review
- Fatal measles virus infection prevented by brain-penetrant fusion inhibitors.Journal of virology · 2013Article
- Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry.BMC microbiology · 2013Article
- Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase: synthesis, structure-activity relationships, and pharmacokinetics.Journal of medicinal chemistry · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Infection by measles virus (MV) is a major cause of human morbidity and mortality worldwide. In 2001, the WHO, UNICEF and their partners launched the Measles Initiative, the goals of which are to interrupt the transmission of MV in large geographic areas by increasing vaccination coverage and to assess the feasibility of eradicating MV worldwide. An estimated 74% reduction in mortality resulting from measles was achieved between 2000 and 2007, equivalent to a reduction of approximately 200,000 deaths annually. Despite this progress in the control of measles, the highest number of measles cases in more than a decade was observed in 2008 in several European countries and the US, and the virus was again declared endemic in the UK. In the light of this resurgence in the UK and the limitations associated with the current live-attenuated vaccine, this review discusses the means by which safe and effective measles antivirals could augment vaccination and strengthen global efforts to control measles. Important aspects of treatment are the potential to prevent infection effectively after exposure to MV, the improvement of case management, the amelioration of complications that frequently follow MV infection and the influence of antivirals on a potential strategy for global measles eradication.
Indexed as
Identifiers
19649926PMC2728049W71139353What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.